All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Bookmark this article
On the 21st July 2017, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a ‘positive opinion’ of the anti-CD20 IgG1 monoclonal antibody Gazyvaro® (obinutuzumab) in patients with treatment naïve Follicular Lymphoma (FL).
The opinion was specifically for obinutuzumab combined with chemotherapy then followed by maintenance with obinutuzumab in patients who responded.
Results from the phase III, open-label, randomized GALLIUM study (NCT01332968) formed the basis of the committee’s positive opinion. Updated results for each immunochemotherapy regimen were presented by Wolfgang Hiddemann from the Ludwig-Maximilians University Hospital, Munich, Germany, during the 14th International Conference on Malignant Lymphoma (ICML) held last month in Lugano, Switzerland (read more here). Overall, a beneficial effect of obinutuzumab was observed with all chemotherapy backbones; the risk of disease progression or death decreased by 34% in FL patients who received obinutuzumab plus chemotherapy compared to those who received rituximab plus chemotherapy.
Furthermore, during the 22nd Congress of the European Hematology Association (EHA) held in Madrid, Spain, the Lymphoma Hub interviewed Associate Professor Judith Trotman from the Concord Repatriation General Hospital, Sydney, a member of our Scientific Advisory Board, on CT versus PET in the GALLIUM study (watch it here.)
Currently, obinutuzumab combined with bendamustine is approved by the EMA and the U.S. Food and Drug Administration (FDA) in patients with Relapsed/Refractory (R/R) FL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox